Hepatitis B virus X protein accelerates hepatocarcinogenesis with partner survivin through modulating miR-520b and HBXIP by Weiying Zhang et al.
Zhang et al. Molecular Cancer 2014, 13:128
http://www.molecular-cancer.com/content/13/1/128RESEARCH Open AccessHepatitis B virus X protein accelerates
hepatocarcinogenesis with partner survivin
through modulating miR-520b and HBXIP
Weiying Zhang1, Zhanping Lu1, Guangyao Kong1, Yuen Gao1, Tao Wang1, Qi Wang1, Na Cai1, Honghui Wang2,
Fabao Liu2, Lihong Ye2 and Xiaodong Zhang1*Abstract
Background: Hepatitis B virus X protein (HBx) plays crucial roles in hepatocarcinogenesis. However, the underlying
mechanism remains elusive. We have reported that HBx is able to up-regulate survivin in hepatocellular carcinoma
tissues. The oncopreotein hepatitis B X-interacting protein (HBXIP), a target of miR-520b, is involved in the
development of cancer. In this study, we focus on the investigation of hepatocarcinogenesis mediated by HBx.
Methods: The expression of HBx and survivin was examined in the liver tissues of HBx-Tg mice. The effect of
HBx/survivin on the growth of LO2-X-S cells was determined by colony formation and transplantation in nude mice.
The effect of HBx/survivin on promoter of miR-520b was determined by Western blot analysis, luciferase reporter
gene assay, co-immunoprecipitation (co-IP) and chromatin immunoprecipitation (ChIP), respectively. The expression
of HBx, survivin and HBXIP was detected by immunohistochemistry and real-time PCR in clinical HCC tissues,
respectively. The DNA demethylation of HBXIP promoter was examined. The functional influence of miR-520b and
HBXIP on proliferation of hepatoma cells was analyzed by MTT, colony formation, EdU and transplantation in nude
mice in vitro and in vivo.
Results: In this study, we provided evidence that HBx up-regulated survivin in the liver cancer tissues of HBx-Tg
mice aged 18 M. The engineered LO2 cell lines with survivin and/or HBx were successfully established, termed
LO2-X-S. MiR-520b was down-regulated in LO2-X-S cells and clinical HCC tissues. Our data revealed that HBx
survivin-dependently down-regulated miR-520b through interacting with Sp1 in the cells. HBXIP was highly
expressed in LO2-X-S cells, liver cancer tissues of HBx-Tg mice aged 18 M and clinical HCC tissues (75.17%,
112/149). The expression level of HBXIP was positively associated with those of HBx or survivin in clinical HCC
tissues. In addition, we showed that HBx survivin-dependently up-regulated HBXIP through inducing demethylation
of HBXIP promoter in LO2-X-S cells and clinical HCC tissues. In function, low level miR-520b and high level HBXIP
mediated by HBx with partner survivin contributed to the growth of LO2-X-S cells in vitro and in vivo.
Conclusion: HBx accelerates hepatocarcinogenesis with partner survivin through modulating tumor suppressor
miR-520b and oncoprotein HBXIP.
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Hepatocellular carcinoma (HCC) is one of the most ma-
lignant tumors in the world. The chronic infection of
hepatitis B virus (HBV) is a crucial risk factor in the devel-
opment of HCC. HBV encoded X protein (HBx) is a key
player in the pathogenesis of HBV-associated liver dis-
eases. It is able to transactivate cellular genes associated
with processes such as transcription, apoptosis, signaling,
and cell growth [1-3]. Our laboratory has reported that
HBx plays an important role in the event, such as activat-
ing Yes-associated protein (YAP), Lin28A/B and Rab18
[4-6]. HBx transgenic (Tg) mice are able to develop
hepatitis, steatosis, and dysplasia, culminating in the ap-
pearance of HCC in liver [7-9]. However, HBx alone is
considered a poor transformer of human and rodent
hepatic cells. In support of this, co-transfection with an
oncogene, such as H-ras or myc, is necessary for accel-
erating hepatocarcinogenesis [10]. As an inducible fac-
tor, survivin is abundantly expressed in a hepatoma cell
line harboring HBV [11]. We previously reported that
HBx was able to up-regulate survivin in hepatoma cells
[12]. HBx may up-regulate survivin through activation
of Wnt/β-catenin signaling [13-15]. Therefore, we sup-
posed that HBx might collaborate with survivin to ac-
celerate hepacarcinogenesis.
Mammalian hepatitis B X-interacting protein (HBXIP)
is originally identified as a binding protein of HBx [16].
Recently, it has been reported that HBXIP serves as a
regulator component for the mammalian target of rapa-
mycin (mTOR) Complex 1 activation which regulated
cell growth [17]. We have reported that HBXIP acts as
an oncoprotein to promote the development of breast
cancer through activating some cellular genes such as
S100A4, NF-κB, Interleukin-8 and c-Myc [18-20].
HBXIP up-regulates some membrane-bound comple-
ment regulatory proteins through phosphorylated extra-
cellular signal-regulating kinase 1/2 (p-ERK1/2)/NF-κB
signaling to accelerate breast tumor growth [21]. In
addition, HBXIP has also been identified as an adaptor
for survivin to suppress apoptosis [22]. Meanwhile, HBx
may interfere with the normal function of HBXIP during
prometaphase, resulting in genomic instability [23,24].
However, the function of HBXIP in the development of
HCC mediated by HBx remains unclear.
Accumulating data indicated that aberrant expression
of microRNAs (miRNAs) could regulate cancer develop-
ment including tumorigenesis, metastasis and prolifera-
tion by serving as tumor suppressors or oncogenes.
MiRNAs have essential roles in the progression of HCC
and directly contribute to the development of HCC by
targeting a large number of critical protein-coding genes
[25,26]. Our laboratory has revealed that miR-520b tar-
geting HBXIP and IL-8 inhibits the migration of breast
cancer cells [19], which is down-regulated in breastcancer cells and sensitizes breast cancer cells to comple-
ment attack [27]. Moreover, miR-520b targeting mitogen-
activated protein kinase kinase kinase 2 (MEKK2) and
cyclinD1 inhibits the proliferation of liver cancer cells
[28]. However, the role of miR-520b in hepatocarcinogen-
esis mediated by HBx remains ill-defined.
In the present study, we further investigated the role of
HBx in the development of HCC. Interestingly, we identify
that HBx enhances hepatocarcinogenesis with partner
survivin through modulating miR-520b and HBXIP. Our
finding provides new insights into the mechanism of
hepatocarcinogenesis mediated by HBx.
Results
HBx accelerates hepatocarcinogenesis with partner
survivin
We have reported that HBx can up-regulate survivin in
stable HBx transfected LO2 cells [12], however, its signifi-
cance is not clear. To better understand the effect of HBx
on survivin, we examined the expression levels of survivin
in the liver tissues of HBx-Tg mice which were obtained
from Prof. Xiao Yang [7]. Interestingly, we observed that
the expression levels of survivin were increased in the liver
tissues of HBx-Tg mice aged 12 M, but remarkably ele-
vated in the liver cancer tissues of HBx-Tg mice aged
18 M (Figure 1A), supporting that HBx is capable of up-
regulating survivin. Then, we speculated that survivin
might be involved in the hepatocarcinogenesis mediated
by HBx. To examine the role of HBx and survivin in the
event, we successfully established an engineered cell line
of stably HBx/survivin-transfected human immortalized
liver LO2 (or mouse NIH3T3) cells (termed LO2-X-S,
or 3 T3-X-S) (Figure 1B, Additional file 1: Figure S1 and
Additional file 2: Table S1). Colony formation assay
showed that LO2-X-S cells yielded a significantly more
number of colonies relative to control cell lines (Figure 1C).
We previously reported that 3 of 8 mice injected with
LO2-X cells grew tumors [29]. In this study, we observed
that all 8 mice injected with LO2-X-S cells formed tumors,
while LO2, LO2-P and LO2-S cells failed to form any vis-
ible tumors. The expression of alpha fetoprotein (AFP, a
hepatoma marker) was detectable in all tumor tissues
from mice by western blotting and immunohistochemistry
(IHC) (Figure 1D), suggesting that LO2 cell line is suc-
cessfully transformed by HBx and survivin. Therefore, we
conclude that HBx accelerates hepatocarcinogenesis with
partner survivin.
HBx down-regulates miR-520b through binding to Sp1
with partner survivin
To explore the mechanism by which HBx accelerates
carcinogenesis with partner survivin, we examined the
expression differentiate profiles between LO2-X-S cells
and LO2-X cells by miRNA microarray assay. Our data
Figure 1 HBx accelerates hepatocarcinogenesis with partner survivin. (A) The expression of survivin in the liver tissues of p21-HBx Tg mice
aged 6, 12 and 18 mouths versus WT littermate mice were determined by western blotting, respectively (**P < 0.01, Student’s t test). (B) The
integrations of HBx and survivin genes into the genomes of LO2 cells were validated by PCR using genomic DNA as a template. GAPDH was
used as a loading control. (C) The effect of HBx and/or survivin on cell proliferation was detected by colony-formation assay (*P < 0.05, **P < 0.01,
Student’s t test). (D) Tumor formation in nude mice (n = 8 per group) injected with LO2-X or LO2-X-S cells was assessed in 3 weeks. The
expression of AFP was tested in the tumor tissues from mice by western blotting and IHC analysis, respectively.
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miR-181c) were remarkably down-regulated (up-regulated)
(Additional file 3: Figure S2(A) and Additional file 2:
Table S2). Then, we confirmed the data using qRT-PCR
(Figure 2A). Moreover, we validated that the expression
of miR-520b was down-regulated by qRT-PCR in LO2-
X-S cells (22 HCC tissues) relative to LO2, LO2-X and
LO2-S cells (their peritumor tissues) (Additional file 3:
Figure S2(B) and Figure 2B). It has been reported that
HBXIP which directly interacts with HBx [16] is one of
the target genes of miR-520b [19]. Next, we focused on
the investigation of miR-520b in the hepatocarcingen-
esis mediated by HBx and survivin.
We constructed the promoter of miR-520b (Additional
file 3: Figure S2(C)) and searched for the possible tran-
scription factor binding sites in miR-520b promoter using
promoter analysis program TF2 SEARCH (http://www.cbrc.jp/research/db/TFSEARCH.html). We observed that
the miR-520b promoter contained a transcriptional factor
Sp1 binding site (Figure 2C). Furthermore, we showed
that Sp1 RNAi remarkably increased the expression of
miR-520b by qRT-PCR in LO2-X-S cells and HepG2.2.15
cells (Figure 2D). Luciferase reporter gene assay showed
that the Sp1 siRNA removed the suppression of miR-520b
in a dose-dependent manner in the cells, suggesting that
Sp1 is responsible for the suppression of miR-520b ex-
pression. In addition, the Sp1 mutant of miR-520b pro-
moter (Figure 2C) abolished the transcriptional inhibition
of miR-520b in LO2-X-S cells (Figure 2E). It has been re-
ported that HBx is able to interact with transcriptional
factor Sp1 and affects its DNA binding activity [30]. Then,
we examined whether survivin was involved in the inter-
action between HBx and Sp1 by co-immunoprecipitation
(co-IP). Interestingly, we found that HBx, survivin and
Figure 2 HBx down-regulates miR-520b through binding to Sp1 with partner survivin. (A) The expression levels of miRNA-520b,
miRNA-520e, miRNA-29a and miRNA-181c were examined by qRT-PCR in LO2-X-S/LO2-X cells. (B) The expression of miR-520b in clinical HCC
and peritumor samples was detected by qRT-PCR. (C) A model shows Sp1 binding site-directed mutation in the promoter region of miR-520b.
(D) The effect of knockdown of Sp1 on miR-520b in LO2-X-S or HepG2.2.15 cells was examined by qRT-PCR analysis (***P < 0.001, Student’s t test).
(E) The effect of Sp1 on miR-520b promoter in LO2-X-S cells was tested using Sp1 siRNA (Si-Sp1) or Sp1 mutant by luciferase reporter gene assays
(**P < 0.01, Student’s t test). (F-H) The interaction among HBx, survivin and Sp1 in a complex was examined by co-IP. (I) Interaction of the com-
plex, including HBx, survivin and Sp1, with the promoter region of miR-520b was examined by ChIP in LO2-X-S cells.
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noprecipitation (ChIP) assay further demonstrated that
the miR-520b promoter gene could be detected in the
anti-HBx (or anti-survivin, anti-Sp1)-immunoprecipited
candidates from LO2-X-S cells, however, it was undetect-
able when the cells were treated with Sp1 (or survivin)
siRNA (Figure 2I). Overall, we conclude that HBx down-
regulates miR-520b through interacting with Sp1 with
partner survivin.
HBx up-regulates HBXIP in HBx-Tg mice and HCC tissues
with partner survivin
We previously reported that miR-520b could target
HBXIP mRNA [19]. Accordingly, we validated that inour system. Although HBx is able to directly interact
with HBXIP [16], whether HBx is capable of up-
regulating HBXIP remains unclear. Our data revealed
that miR-520b could target HBXIP 3′UTR and reduced
the expression of HBXIP at the levels of mRNA and pro-
tein in the cells (Additional file 4: Figure S3(A)), suggest-
ing that HBx may up-regulate HBXIP with partner
survivin through suppressing miR-520b. Interestingly,
we observed that the expression levels of HBXIP were
remarkably increased in LO2-X-S cell lines and liver
cancer tissues of HBx-Tg mice aged 18 M (Figure 3A, B
and Additional file 4: Figure S3(B)), suggesting that HBx
accelerates carcinogenesis through up-regulating HBXIP
with partner survivin. To evaluate the effect of HBV
Figure 3 HBx up-regulates HBXIP in HBx-Tg mice and HCC tissues with partner survivin. (A) The expression of HBXIP was detected by
western blotting in LO2 and engineered cell lines (*P < 0.05, Student’s t test). (B) The expression of HBXIP in the liver tissues of p21-HBx-Tg mice
aged 6, 12 and 18 mouths versus WT littermate mice were determined by western blotting, respectively (*P < 0.05, Student’s t test). (C) Expression
of HBXIP was examined by IHC staining in the clinical tissues of normal liver, hepatitis, liver cirrhosis, HCC and peritumor tissues. (D, E) Correlation
between relative expression of HBXIP and that of HBx (or survivin) was examined by qRT-PCR in 22 cases of HCC tissues (***P <0.001, r = 0.797 or
r = 0.717; Pearson’s correlation coefficient). Data presented are from three independent experiments.
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fected the pCH-9/3091 plasmid containing full-length
HBV DNA into LO2 cells. Our data demonstrated that
the expression levels of both HBXIP and survivin were
up-regulated in the cells at the levels of mRNA andprotein. Meanwhile, the expression of HBx was validated
in the system (Additional file 4: Figure S3(C)). We further
evaluated the effect of HBx, HBsAg and HBcAg on the ex-
pression of HBXIP and survivin in hepatoma HepG2.2.15
cells integrated HBV DNA. Interestingly, we found that
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could obviously abolish the up-regulation of HBXIP.
But, si-HBs (for HBsAg mRNA) and si-HBc (for HBcAg
mRNA) failed to work (Additional file 4: Figure S3(D)),
suggesting that HBx and survivin (not HBsAg and
HBcAg) are responsible for the up-regulation of HBXIP
in the cells [31].
Previously, we reported that the positive rates of HBxAg
and survivin in HCC tissues were 76.5% and 88.2%, re-
spectively [12]. In this study, we further examined the ex-
pression of HBXIP in clinical HCC tissues. IHC showed
that the expression of HBXIP was positive in 112 out
of 149 (75.17%) cases of HCC tissues, of which 59 out of
112 (52.68%) tissues exhibited stronger HBXIP staining
(Figure 3C and Table 1). In contrast, 20 peritumor sam-
ples, 30 normal liver samples and 10 hepatitis samples
were weak staining for HBXIP. Furthermore, we found
that the up-regulation of HBXIP was significantly corre-
lated with those of HBx (or survivin) in 22 human HCC
tissues by quantitative real-time polymerase chain reaction
(qRT-PCR) (r = 0.797 or 0.717, p <0.001, Pearson′s correl-
ation, Figure 3D, E). Thus, our data suggest that HBXIP is
up-regulated in HCC tissues with partner survivin.
HBx survivin-dependently up-regulates HBXIP via DNA
demethylation of HBXIP
In this study, we demonstrated that HBx up-regulated
HBXIP with partner survivin through down-regulating
miR-520b targeting HBXIP mRNA. Next, to explore the
other mechanism of up-regulating HBXIP by HBx, we ex-
amined the effect of HBx and suvivin on DNA methylation
of HBXIP. We cloned and identified the core region of
HBXIP promoter. Various fragments of HBXIP 5'-flanking
region, including −3233/-1673, −1484/+1, −804/+1, −588/+1,
and −168/+1, were cloned and transiently transfected
into HepG-X (or H7402-X, LO2-X-S) cells, respectively.
As shown in Figure 4A, p(−3233/-1673) displayed the
highest promoter activities among them. Interestin-
gly, we observed a typical CpG island in the region
of −2360 ~ −2140 by using CpG Island Searcher (http://
cpgislands.usc.edu/) or MethylPrimer Express Software
v1.0. Bisulfite sequencing analysis and methylation-
specific PCR (MSP) showed that the CpG sites were
demethylated in LO2-X-S/HepG2.2.15 cells and clinicalTable 1 The Expression of HBXIP in human liver tissues
Tissues Total (No.) Positive (+, No.)
Normal liver 10 10
Hepatitis 10 10
Liver cirrhosis 40 38
Hepatocarcinoma 149 37
Peritumor 20 20
Expression: positive, + to +++. X2 test, *P < 0.01 (versus Liver cirrhosis).HCC tissues (n = 4). In contrast, the CpG sites were highly
methylated in LO2, LO2-S cells and nontumorous liver
tissues (Figure 4B, C). It suggests that HBx up-regulate
HBXIP in hepatoma cells through inducing demethylation
of CpG islands of HBXIP promoter with partner survivin.
MiR-520b/HBXIP modulates proliferation of LO2-X-S cells
in vitro
Next, we evaluated the function of miR-520b/HBXIP me-
diated by HBx with partner survivin in carcinogenesis.
MTT and EdU incorporation assays demonstrated that
overexpression of miR-520b resulted in the inhibition of
proliferation of LO2-X-S cells, while the introduction of
HBXIP significantly rescued the suppression by miR-520b
(Figure 5A, B). Moreover, the HBXIP siRNA inhibited the
proliferation of LO2-X-S (or 3 T3-X-S) cells by EdU and
colony-formation assays (Figure 5C, D). It suggests that
HBx accelerates proliferation of LO2-X-S cells in vitro
through down-regulating miR-520b and up-regulating
HBXIP.
MiR-520b/HBXIP modulates growth of LO2-X-S cells
in vivo
We further examined the role of miR-520b/HBXIP in
tumor growth in vivo. We previously reported that 3 of 8
nude mice injected with LO2-X cells grew tumors [29]. In
this study, we observed that all 8 nude mice injected with
LO2-X-S cells formed tumors, while LO2, LO2-P and LO2-
S cells failed to form any visible tumors. Then, we observed
that the introduction of miR-520b into LO2-X-S cells led to
a significant reduction of tumor formation (n = 5, each
group). Meanwhile, the expression levels of miR-520b
by qRT-PCR in the tumor tissues from mice (Figure 6A-C),
suggesting that the levels of miR-520b are correspond-
ence to the growth ability. Interestingly, the expression
levels of HBXIP were decreased in the system by west-
ern blotting (Figure 6D), suggesting that the inhibition
of HBXIP contributes to the suppression of tumor
growth in the mice. Further data validated that the in-
hibition of HBXIP by siRNA obviously resulted in the
reduction of tumor formation and depressed the growth
of LO2-X-S cells in mice (n = 5, each group), meanwhile,
the expression levels of HBXIP in the tumor tissues






Figure 4 HBx survivin-dependently up-regulates HBXIP via DNA demethylation of HBXIP. (A) Schematic representation of the HBXIP
promoter was shown. The activities of different fragments from HBXIP promoter were tested by luciferase reporter gene assays in HepG2-X,
H7402-X and LO2-X-S cells (*P < 0.05, **P < 0.01, Student’s t test). (B, C) The methylation levels of HBXIP CpG sites were examined by bisulfite
sequencing and MSP analysis in the cells and clinical tissues (n = 4), respectively. Eight CpG sites were analyzed. Closed and open circle present
methylated and unmethylated CpG site, respectively. N represents adjacent nontumorous tissue; T represents HCC tissue. Bands in the ‘M’ and ‘U’
lanes are PCR products obtained with methylation-specific and unmethylation-specific primers, respectively.
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Figure 5 MiR-520b/HBXIP modulates proliferation of LO2-X-S cells in vitro. (A-D) The effects of miR-520b, miR-520b/HBXIP or si-HBXIP on
proliferation of LO2-X-S cells were examined by MTT, EdU incorporation or colony-formation assays, respectively. Si-NC refers to negative control
of HBXIP siRNA. Data are shown as mean ± SD of three independent experiments (*P < 0.05, **P < 0.01, Student’s t test).
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clude that miR-520b suppresses and HBXIP accelerates
LO2-X-S cells growth in vivo.Discussion
It has been reported that HBx is a key factor in hepato-
carcinogenesis [32]. The co-transfection with an onco-
gene, such as H-ras or myc, is necessary for accelerating
hepatocarcinogenesis [10]. HBx can promote initiation
and progression of hepatocellular carcinoma through co-
operating with Kras involved in Ras pathway [33]. We
previously reported that HBx was able to up-regulate
survivin in hepatoma cells [12]. Therefore, we are inter-
ested in whether HBx can accelerate hepatocarcinogen-
esis through cooperating with survivin.
Interestingly, in this study we validated that survivin
was up-regulated in the liver tissues from HBx-Tg mice
in a time course manner. To demonstrate the significance
of survivin up-regulation in HBx-induced hepatocarcino-
genesis, we successfully generated an engineered cell line
model (termed LO2-X-S) that LO2 cells stable transfected
with both HBx and survivin. We previously reported that
3 of 8 mice injected with LO2-X cells stably transfected
HBx grew tumors [29]. Strikingly, in this study we ob-
served that all 8 mice injected with LO2-X-S cells formed
tumors. It implies that survivin is an important partner of
HBx in tumorigenesis.Next, to better understand the underlying mechanism
of tumorigenesis mediated by HBx with partner survivin,
we assessed the miRNA differentiate expression profiles
between LO2-X-S cells and LO2-X cells using miRNA
microarray assay. Our data showed that miR-520b was
down-regulated in LO2-X-S cells, relative to LO2-X cells.
We previously reported that HBXIP was a target gene of
miR-520b in breast cancer cells [19]. Therefore, we con-
cerned that miR-520b targeting HBXIP might be involved
in the HBx-induced hepatocarcinogenesis. Moreover, we
identified that HBx was able to form a complex with sur-
vivin and transcription factor Sp1, resulting in the down-
regulation of miR-520b through inactivating miR-520b
promoter. Consistent with our previous reports [19,27,28],
our finding suggests that miR-520b is a novel tumor sup-
pressor gene.
Then, we moved to the investigation of HBXIP in
HBx-induced hepatocarcinogenessis. It has been re-
ported that HBXIP functions as a cofactor of survivin in
apoptosis suppression [16,22]. HBXIP is a critical target
of viral HBx for promoting genetic instability through
formation of defective spindles and subsequent aberrant
chromosome segregation [23]. HBXIP is a regulator of
centrosome duplication, required for bipolar spindle for-
mation in HeLa human carcinoma cells and primary
mouse embryonic fibroblast cells [24]. Our laboratory also
shows that HBXIP is a novel oncoprotein in breast cancer
[18,19]. In this study, we used the model of HBx-Tg mice
Figure 6 MiR-520b/HBXIP modulates growth of LO2-X-S cells in vivo. (A-G) The effect of miR-520b or si-HBXIP on the growth of LO2-X-S
cells was detected by xenograft assay. The expression levels of miR-520b and HBXIP in the tumor tissues from mice (n = 5, each group) were
determined by qRT-PCR or western blot analysis, respectively. Data are shown as mean ± SD of three independent experiments (*P < 0.05,
**P < 0.01, Student’s t test). (H) A model of HBx accelerating hepatocarcinogenesis with partner survivin.
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induced hepatocarcinogenesis. Strikingly, we observed
that both of survivin and HBXIP were markedly up-
regulated in HBx-Tg mice, however, the up-regulation of
survivin was earlier (at 12 M mice) than that of HBXIP (at
18 M mice). Moreover, the expression of HBXIP stayed
lower in the liver at 12 M HBx-Tg mice which didn’t de-
velop HCC. However, the HBXIP was highly expressed in
the liver cancer at 18 M HBx-Tg mice that developed
HCC. Therefore, it strongly suggests that HBx first up-
regulates survivin and then increases the expression ofHBXIP through collaborating with survivin. In clinical, we
found that 20 peritumor samples, 30 normal liver samples
and 10 hepatitis samples were weak staining for HBXIP.
But, HBXIP was highly expressed in HCC tissues, posi-
tively associating with the expression levels of HBx and
survivin. The above data are consistent with the data in
HBX-Tg mice.
It has been reported that the global patterns of DNA
methylation are altered in many cancers, including HCC
[34-36]. To explore the mechanism by HBx and survivin
up-regulate HBXIP, we observed the promoter region of
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that there were CpG islands in the promoter region. Thus,
we supposed that the methylation regulation might be in-
volved in the up-regulation of HBXIP mediated by HBx
and survivin. Accumulating data reported that HBx had
an effect on DNA methyltransferase [37,38]. However, the
role of survivin in methylation regulation has not been re-
ported. Surprisingly, we showed that HBx and survivin re-
sulted in demethylation of HBXIP promoter in the cells.
The methylation modification of HBXIP was observed in
the cell lines and clinical liver cancer tissues. Therefore, it
suggests that HBx up-regulates HBXIP with partner survi-
vin not only through down-regulating miR-520b targeting
HBXIP mRNA but also inducing demethylation of HBXIP
promoter. The possible mechanism may be related to that
the overexpression of both HBx and survivin suppresses
the methylase (or methyltransferase), or activate demethy-
lase in the cells. The mechanism needs to be further inves-
tigated in detail. Recently, our laboratory has reported that
the oncoprotein HBXIP serves as co-activator of tran-
scriptional factors in breast cancer. The nuclear import of
oncoprotein HBXIP depends on interacting with c-Fos
and phosphorylation of both proteins in breast cancer
cells [39-41]. Thus, our finding suggests that HBXIP as a
crucial oncoprtein contributes to the HBx-induced hepa-
tocarcinogenesis. In function, we found that miR-520b
and HBXIP were responsible for the growth of LO2-X-S
cells in vitro and in vivo. Therapeutically, all the factors,
such as HBx, survivin and HBXIP, may serve as targets in
HBV-associated HCC.
Conclusion
We summarize a model that HBx accelerates hepatocar-
cinogenesis with partner survivin (Figure 6H). On the
one hand, HBx survivin-dependently down-regulates
tumor suppressor miR-520b through modulating tran-
scription factor Sp1 and then miR-520b inhibits the ex-
pression of oncoprotein HBXIP through targeting its
3'UTR; on the other hand, HBx induces demethylation
of HBXIP promoter with partner survivin, resulting in
up-regulation of HBXIP. Our finding provides new in-




The plasmid pCMV-X was used as a template for subclon-
ing HBx into the pCMV-Tag2B vector (termed Flag-X)
[12]. One 3′-deleted DNA fragment and four 5′-deleted
DNA fragments of various sizes were amplified by PCR
from the 5′-flanking region of HBXIP. To generate a
series of reporter constructs (p-3233/-1673, p-1484/+1,
p-804/+1, p-588/+1 and p-168/+1), each fragment was
inserted between the Kpn I and Hind III sites in thepGL3-basic vector (Promega, USA). To clone the miR-
520b promoter into the pGL3-basic vector, a 1 kb section
of the putative promoter region (from −1 to −1000) was
amplified by PCR and cloned into the pGL3-basic vector.
The transcription factor binding site mutants of the miR-
520b promoter were cloned using the Fast Mutagenesis
System (TransGen Biotech, China). All primers used are
listed in Additional file 2: Table S2.Cell culture and generation of stable cell lines
The human immortalized liver LO2, HepG2, HepG2.2.15
and NIHT3T cell lines were purchased from Nanjing
KeyGEN Biotech Co., Ltd (Nanjing, China). The co-
transfection with the plasmids of pCMV-X and pcDNA3-
sur [12] was performed in LO2 cells using Lipofectamine
2000 (Invitrogen, USA) as described [12]. After 48 hours,
the transfected cells were incubated in selection medium
containing 500 μg/ml or 800 μg/ml G418 (Genview,
USA). The transfection efficiencies were tested by PCR
(one primer is from survivin and another is from the vec-
tor), western blotting, as indicated. Then, the engineered
cell line was termed LO2-X-S. All the engineered cell lines
were cultured in RPMI Medium 1640 (GIBCO, USA) con-
taining 100 U/ml penicillin, 100 μg/ml streptomycin and
10% fetal calf serum (FCS). HepG2 cells, HepG2-X cells
[42] and HepG2.2.15 cells were cultured in Dulbecco’s
Modified Eagle’s medium (DMEM, GIBCO) containing
100 U/ml penicillin, 100 μg/ml streptomycin and 10%
FCS.Patient samples
The 22 paired HBV-related HCC tissues and the corre-
sponding nearby noncancerous livers used in this study
were obtained from patients who underwent radical resec-
tion at Tianjin First Center Hospital (Tianjin, China).
Specimens were immediately frozen and stored at −80°C.
Clinicopathological information about patients was ob-
tained from patient records and was summarized in
Table 1. All patients were diagnosed with primary HCC,
and none had received previous radiotherapy or chemo-
therapy before surgery. Informed consent was obtained
from each patient and the study was approved by the In-
stitute Research Ethics Committee at Nankai University.MiRNA microarray
MiRNA microarrays were performed by CapitalBio
(CapitalBio Corp, China) as described in detail on the
CapitalBio website (http://www.capitalbio.com). The miR-
NAs that showed >2-fold or <0.5 changes in expression
were considered to have changed significantly and are
shown in (Additional file 2: Table S2).
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real-time polymerase chain reaction (qRT-PCR)
Total RNA of cells (or liver tissues) were extracted using
TRIzol reagent (Invitrogen) and qRT-PCR was performed
according to the manufacturer’s instructions. The expres-
sion of specific genes or miRNAs was tested by the com-
parative Ct method using 2-ΔΔCt [43]. Primers used are
listed in (Additional file 2: Table S2). The HBV DNA in
the supernatants of LO2 cells transfected with PCH9/
3091 containing a genome length HBV sequence was ex-
tracted with a commercial kit (QIAGEN, USA) [44]. HBV
DNA copies were quantified by qRT-PCR according to a
diagnostic kit for quantification of HBV DNA (Da An
Gene, China).
Western blotting
Western blotting was carried out in the liver of HBx-Tg
mice, cell lines and tumor tissues from mice using
standard protocols [29]. The following primary anti-
bodies were used: actin (NeoMarkers, USA), HBXIP,
[45] HBx, [46] HBs (Zhongshan-Golden Bridge, ZM-
0122, China), HBc (Zhongshan-Golden Bridge, ZM-0421,
China), Sp1 (McAb, Epitomics, ab77441, USA), survivin
(PcAb, Labvision, PA1-16836, USA), Flag (PcAb, Abcam,
ab93713, UK) and α-fetoprotein ( PcAb, NeoMarkers,
PA5-11480, USA). The data were analyzed by Image-Pro
Plus 6.0 software.
RNA interference (RNAi) and miRNA
The plasmid of pSilencer3.0-X encoding HBx mRNA was
used in transfection of HepG2.2.15 cells as described
above [12]. The short interfering RNA (siRNA) duplexes
targeting survivin, HBXIP [18,47] were synthesized by
Ribobio Co. Lit. (Guangzhou, China) as previously de-
scribed. MiR-520b mimics and its inhibitor (anti-miR-
520b) for in vitro transfection, and their respective nega-
tive controls were from Ribobio Co. Lit. The sequences of
miR-520b mimics and its inhibitor are 5' AAAGUG-
CUUCCUUUUAGAGGG 3' and 5' CCCUCUAAAAG-
GAAGCACUUU 3'. The transfected cells were lysed after
48 hours. Western blotting or RT-PCR was used to deter-
mine the expression levels of survivin and HBXIP.
Luciferase reporter gene assay
H7402-X, HepG2-X cells or LO2 and various LO2-
engineered cell lines were plated in 24-well plates (3×
104 cells/well). The cells were transfected with plasmids
using Lipofectamine 2000 (Invitrogen). At 48 hours
post-transfection, a standard dual luciferase reporter
assay was performed, and the results were normalized
using a co-transfected pRL-TK plasmid containing the
Renilla luciferase gene (Promega). All experiments were
performed at least three times.Co-immunoprecipitation assay
Immunoprecipitations were performed using anti-flag M2
agarose (Sigma,USA) according to the manufacturer’s in-
structions. The immunoprecipitated proteins were then
identified by western blotting as described above using the
anti-HBx antibody, anti-survivin antibody, anti-Sp1 and
anti-HBXIP antibody.
Chromatin immunoprecipitation assay (ChIP)
The ChIP assay was performed using the EpiQuikTM
Chromatin Immunoprecipitation Kit from Epigentek
Group Inc. (Brooklyn, NY). Protein–DNA complexes were
immunoprecipitated with HBx, survivin or Sp1, with Anti-
RNA polymerase II as a positive control antibody and
normal mouse IgG as a negative control antibody. PCR
amplification was performed using 1 μl of each DNA
sample. Amplification of soluble chromatin prior to im-
munoprecipitation was used as an input control.
Immunohistochemistry analysis
The normal human liver, hepatitis, liver cirrhosis and he-
patocellular carcinoma tissue microarrays were obtained
from the Xi'an Aomei Biotechnology Co., Ltd. (Xi'an,
China). Immunohistochemical staining of samples was
performed as previously reported [12]. The percentage
of cells showing positive nuclear and/or cytoplasmic stain-
ing for HBXIP was calculated by reviewing the entire slide.
On the basis of the percentage of cells with positive nu-
clear and/or cytoplasmic staining, staining patterns
were classified on a four-grade scale: 0, <10% cells with
positive nuclear and/or cytoplasmic staining; 1+, 10–
30% positive cells; 2+, 30–50% positive cells; 3+ >50%
positive cells. Categorization of immunostaining intensity
was performed by two or three independent observers.
Light microscopic images were documented using a Nikon
Eclipse Ti-U fluorescence microscope (Nikon Corp) with
an attached SPOT RT digital camera (Diagnostic Instru-
ments, Inc.).
Gene-specific DNA methylation
Genomic DNA was extracted from the cells (or liver tis-
sues) using a TIANamp Genomic DNA Kit (TIANGEN
BIOTECH CO.) according to the manufacturer’s instruc-
tions. The methylation statuses of various genes were
determined by bisulfite sequencing PCR after sodium
bisulfite conversion of the DNA using an EZ DNA
Methylation-GoldTM Kit (Zymo Research, USA) ac-
cording to the manufacturer’s instructions. This method
is based on the differential sensitivities of methylated
and unmethylated CpG to bisulfite treatment. The modi-
fied DNA was then used as a PCR template to amplify
either unmethylated or methylated bisulfite-converted
complementary sequences of the promoter of interest.
The primers were designed using MethPrimer software
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quences are given in (Additional file 2: Table S2). PCR
products were gel-extracted and subcloned into pMD18-
T vectors (TAKARA, China), and five clones from each
sample were sequenced for DNA sequencing.Analysis of cell proliferation
For cell proliferation assays, LO2 or various engineered
cells were seeded in 96-well plates (1000 cells/well) for
24 hours before transfection and 3-(4,5-dimethylthiazol-
2-yl) -2,5-diphenyltetrazolium bromide (MTT) (Sigma)
assays were used to assess cell proliferation every day
from the first day until the third day after transfection.
The protocol was described previously [48]. 5-ethynyl-
2’-deoxyuridine (EdU) incorporation assay was carried
out using the Cell-Light TM EdU imaging detecting kit
according to the manufacturer’s instructions (RiboBio,
China).Colony formation assay
Anchorage-independent colony formation by these cell
lines was determined as described previously [49], with
some modifications. For colony formation analysis, LO2
and various engineered cells were seeded in six-well
plates. Cells were transfected with RNA interferences
targeting HBXIP using Lipofectamine 2000. Cells were
grown for 9 to 14 days. Once colonies were visible, they
were stained with methylene blue and photographed. All
assays were repeated at least three times. The colonies
were counted using a dissecting microscope.Transplantation in nude mice
The tumorigenicity of LO2 or the LO2 engineered cell
lines were measured as follows. Cells were harvested by
trypsinization, washed twice with sterile phosphate-
buffered saline, and resuspended at a concentration of
1 × 107 cells per ml. Aliquots of 0.1-0.2 ml were injected
subcutaneously into 4- to 6-week-old Balb/c athymic
nude mice. Mice were observed at periodic intervals,
and photographs were taken 3–4 weeks after the injec-
tion. Tumor volume (V) was monitored by measuring
the length (L) and width (W) with calipers and calcu-
lated with the formula (L ×W2) × 0.5.Statistical analysis
All values are presented as means ± SD. Each value is
the mean of at least three separate experiments in each
group. Data were analyzed to compare two groups using
a Student’s t test. P values of less than 0.05 were consid-
ered to be statistically significant. All statistical analysis
was performed using SPSS13.0 software (Chicago, IL).Additional files
Additional file 1: Figure S1. The engineered cell lines are established.
The integrations of HBx and survivin genes into the genomes of NIH3T3
cells were validated by PCR using genomic DNA as a template. GAPDH
was used as a loading control.
Additional file 2: Table S1. List of primers used in this paper. Table
S2. MicroRNAs are regulated in LO2-X-S cells. All differentially expressed
miRNAs have a q value < 0.01(false-positive rate). *P < 0.05, Student’s t
test. MiRNAs marked # were further tested by qRT-PCR.
Additional file 3: Figure S2. HBx down-regulates miR-520b through
Sp1 with partner survivin. (A) The miRNA expression profiles were deter-
mined by miRNA microarray in the cells. The image shows signals from
probes hybridized onto miRNA chips (up panel). The scatter plot graph of
Cy3-1abeled and Cy5-1abeled probes hybridized with the microarray was
showed (down panel). Each point on the plot represents a miRNA
hybridization signal. (B) The expression level of survivin was detected in
LO2, LO2-X, LO2-S and LO2-X-S cells (*P < 0.05, Student’s t test). (C) The
activity of the miR-520b promoter was analyzed by luciferase reporter
gene assay in LO2-X cells. (D) The interference efficiency of two siRNAs
targeting survivin (si-survivin-1 and si-survivin-2) was detected in LO2-X-S
cells by western blotting (*P < 0.05, Student’s t test).
Additional file 4: Figure S3. HBx up-regulates HBXIP in HBx-Tg mice
and HCC tissues with partner survivin. (A) The effect of miR-520b and
pre-miR-520b on the activities of HBXIP 3′UTR was analyzed at the levels
of promoter, mRNA and protein in LO2-X-S cells by luciferase reporter
gene assay, RT-PCR and western blotting, respectively (*P < 0.05, Student’s
t test). (B) The expression of HBXIP was detected by western blotting in
the engineered NIH3T3 cell lines. (C) The expression levels of survivin and
HBXIP (or HBx) in LO2 cells transfected with pCH-9/3091 was detected by
qRT-PCR and western blotting, respectively (*P < 0.05, Student’s t test). (D)
The effect of HBx and/or survivin, HBs, HBc on the expression of HBXIP
and survivin was examined by western blotting in HepG2.2.15 cells,
respectively. Meanwhile, the interference efficiency of HBx, survivin, HBsAg
(HBs) and HBcAg (HBc) was examined by western blotting in the cells.
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